• 1. Emulsion technologies for multicellular tumour spheroid radiation assays?
  Kay S. McMillan,Anthony G. McCluskey,Annette Sorensen,Marie Boyd,Michele Zagnoni Analyst, 2016,141, 100-110
• 2. Empowering microfluidics by micro-3D printing and solution-based mineral coating?
  Hongxia Li,Aikifa Raza,Qiaoyu Ge,Jin-You Lu,TieJun Zhang Soft Matter, 2020,16, 6841-6849
• 3. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095
• 4. Emerging investigator series: heterogeneous reactions of sulfur dioxide on mineral dust nanoparticles: from single component to mixed components?
  Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833
• 5. Excitation energies from ground-state density-functionals by means of generator coordinates
  A. B. F. da Silva,K. Capelle Phys. Chem. Chem. Phys., 2009,11, 4564-4569

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azolines Pyrazolines Pyrazolones

Recent Advances in the Study of 3-amino-6,7-dihydro-1H,5H-pyrazolo1,2-apyrazol-1-one (CAS: 69386-85-2)

3-amino-6,7-dihydro-1H,5H-pyrazolo1,2-apyrazol-1-one (CAS: 69386-85-2) is a heterocyclic compound that has garnered significant attention in the field of chemical biology and medicinal chemistry due to its potential therapeutic applications. Recent studies have explored its role as a key intermediate in the synthesis of novel bioactive molecules, particularly in the development of kinase inhibitors and anti-inflammatory agents. This research briefing aims to summarize the latest findings related to this compound, highlighting its chemical properties, biological activities, and potential applications in drug discovery.

One of the most notable advancements in the study of 3-amino-6,7-dihydro-1H,5H-pyrazolo1,2-apyrazol-1-one is its application in the design of kinase inhibitors. Kinases play a critical role in cellular signaling pathways, and their dysregulation is often associated with diseases such as cancer and autoimmune disorders. Recent research has demonstrated that derivatives of this compound exhibit potent inhibitory activity against specific kinases, including cyclin-dependent kinases (CDKs) and Janus kinases (JAKs). These findings suggest its potential as a scaffold for developing targeted therapies.

In addition to its kinase inhibitory properties, 3-amino-6,7-dihydro-1H,5H-pyrazolo1,2-apyrazol-1-one has been investigated for its anti-inflammatory effects. A 2023 study published in the Journal of Medicinal Chemistry reported that this compound and its analogs can modulate the activity of pro-inflammatory cytokines, such as TNF-α and IL-6, in vitro and in vivo. The study further elucidated the structure-activity relationship (SAR) of these analogs, providing valuable insights for optimizing their therapeutic efficacy.

The synthetic pathways for 3-amino-6,7-dihydro-1H,5H-pyrazolo1,2-apyrazol-1-one have also been refined in recent years. Researchers have developed more efficient and scalable methods for its production, including one-pot reactions and catalytic processes. These advancements not only improve the accessibility of the compound for further research but also reduce the environmental impact of its synthesis. For instance, a 2022 study in Organic Process Research & Development highlighted a green chemistry approach using water as a solvent, which significantly reduced waste generation.

Despite these promising developments, challenges remain in the clinical translation of 3-amino-6,7-dihydro-1H,5H-pyrazolo1,2-apyrazol-1-one-based therapeutics. Issues such as bioavailability, metabolic stability, and off-target effects need to be addressed through further preclinical and clinical studies. However, the compound's versatility and demonstrated biological activities make it a compelling candidate for future drug development efforts.

In conclusion, 3-amino-6,7-dihydro-1H,5H-pyrazolo1,2-apyrazol-1-one (CAS: 69386-85-2) represents a promising scaffold in medicinal chemistry, with applications ranging from kinase inhibition to anti-inflammatory therapy. Ongoing research continues to uncover its potential, and future studies will likely focus on optimizing its pharmacological properties for clinical use. This briefing underscores the importance of this compound in advancing drug discovery and highlights the need for interdisciplinary collaboration to fully realize its therapeutic potential.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)